Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ALTO-101

Other · developed by Alto Neuroscience

Phase 2 Most advanced trial

ANRO Developer

1 Registered trials

What is ALTO-101?

ALTO-101 is an investigational drug studied in Schizophrenia, Cognitive Impairment.

At a glance

Drug type: Other
Therapy area: Psychiatry
Developer: Alto Neuroscience (ANRO)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06502964	Phase 2	Schizophrenia	Recruiting	ANRO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cognitive ImpairmentSchizophrenia

More from Alto Neuroscience

ALTO-100 Phase 2 ALTO-203 Phase 2 ALTO-207 Phase 2 ALTO-300 Phase 2

Sources

ClinicalTrials.gov NCT06502964

Updated Oct 3, 2026. Something wrong or missing? Report it on the ANRO page.

Follow ANRO, the company behind ALTO-101

See ANRO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ANRO catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z